Toronto biotech raises $200 million ahead of ADHD drug decision

TORONTO, Jan 24 (Reuters) - Highland Therapeutics Inc has

raised $200 million from Morgan Stanley ahead of the U.S.

drug regulator's decision for a new drug that manages attention

deficit hyperactivity disorder (ADHD), the Toronto-based biotech

startup said on Tuesday.

Read more